HC-1119
Phase 3Small molecule
HC-1119 is one of 29 small molecule programs targeting Prostate Cancer. It is currently in Phase 3.
1
Indications
4
Total Trials
1
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
314 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Yervoy
Bristol-Myers SquibbPhase 3
Radium-223
BayerPhase 3
Androgen Deprivation Treatment
MMedical University of Vienna
Phase 3
HC-1119
HHinova Pharmaceuticals Inc.
Phase 3
Antibiotic Prophylaxis
AAssistance Publique - Hôpitaux de Paris
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
Duragesic
CCephalon
Preclinical
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Ranexa
MMenarini International Operations Luxembourg SA
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Prostate Cancer2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HC-1119. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- HHinova Pharmaceuticals Inc.